Results 261 to 270 of about 3,105,692 (378)

Atlas of the clinical genetics of human dilated cardiomyopathy

, 2014
Jan Haas, Karen Frese, Barbara Peil, Wanda Kloos, Andreas Keller, Rouven Nietsch, Feng Zhu, Sabine Müller, Elham Kayvanpour, Britta Vogel, Farbod Sedaghat‐Hamedani, Wei-Keat Lim, Xiaohong Zhao, Dmitriy Fradkin, Doreen Köhler, Simon Fischer, Jennifer Franke, Sabine Marquart, Ioana Barb, Daniel Tian Li, Ali Amr, Philipp Ehlermann, Derliz Mereles, Tanja Weis, Sarah Hassel, Andreas Kremer, Vanessa King, Emil Wirsz, Richard Isnard, Michel Komajda, Alessandra Serio, Maurizia Grasso, Petros Syrris, Eleanor Wicks, Vincent Plagnol, Luís R. Lopes, Tenna Gadgaard, Hans Eiskjær, Mads Emil Jørgensen, Diego García-Giustiniani, Martín Ortiz-Genga, María G. Crespo‐Leiro, Rondal H. Lekanne Dit Deprez, Imke Christiaans, Ingrid A van Rijsingen, Arthur A. Wilde, Anders Waldenström, Martino Bolognesi, Riccardo Bellazzi, Stellan Mörner, Justo Lorenzo Bermejo, Lorenzo Monserrat, Eric Villard, Jens Mogensen, Yigal M. Pinto, Philippe Charron, Perry Elliott, Eloisa Arbustini, Hugo A. Katus, Benjamin Meder   +59 more
openalex   +2 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Cytogenetics in the genomics era: why karyotyping still matters. [PDF]

BMC Med Genomics
Chebly A.
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Correction: fitness landscape transformation through a single amino acid change in the rho terminator.

PLoS Genetics, 2015
PLOS Genetics Staff
doaj   +1 more source

Functional studies of human variants in C. elegans link iron metabolism to DPD deficiency and 5-FU sensitivity. [PDF]

Genetics
Li X, Menendez Perdomo IM, van Kuilenburg ABP, Tarailo-Graovac M.   +3 more
europepmc   +1 more source

The genetics of potential albendazole and ivermectin resistance in lymphatic filariae

, 2007
Anne E. Schwab
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Aquatic Animal Viruses and Antiviral Immunity: A Closing Editorial. [PDF]

Viruses
Polinski MP.
europepmc   +1 more source

Genetics of Some Quantitative Traits in Six-Rowed Barley (Hordeum vulgare L.) over Three Environments

, 2002
Yogendra Sharma, Pushpesh Joshi, SN Sharma   +2 more
openalex   +1 more source